Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-12

Clinical Trial Update: Dapagliflozin (DAPA) Effects in HFpEF [Phase 2]

View source ↗

Summary

Phase 2 trial investigating dapagliflozin effects in heart failure with preserved ejection fraction has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Mayo Clinic | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: COMPLETED | Results posted: 2023-10-12